Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma

Basit Öğe Kaydı
dc.contributor.authorYalcin, Suayib
dc.contributor.authorLacin, Sahin
dc.date.accessioned2024-04-24T17:18:26Z
dc.date.available2024-04-24T17:18:26Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractRenal cell carcinoma (RCC) is the most common type of kidney malignancy, and the clear-cell subtype represents the majority of RCCs. RCC is a heterogeneous disease in terms of genetic and histological features which determine the behavior of the disease. The von Hippel-Lindau (VHL) is a tumor suppressor gene and mutations of this gene are seen in 95% of clear-cell RCCs. Inactivation of VHL causes the accumulation of hypoxia-inducible factor-1 (HIF-1), and in turn, accumulation of HIF-1 induces overexpression of vascular endothelial growth factor (VEGF); the increase in VEGF expression makes RCC a highly vascularized tumor, and forms the rationale for antiVEGF treatment. In the past decade, improvement in the survival of RCC patients has been observed due to new effective therapies, such as antiVEGF and mammalian target of rapamycin (mTOR) targeting agents and immune checkpoint inhibitors. The majority of VEGF targeted agents are not just selective to VEGF receptors, but usually also have inhibitory effects on other kinases, such as c-KIT and FLT3. Tivozanib is an extremely potent and selective tyrosine kinase inhibitor (TKI) of VEGFR-1, 2, and 3, with a relatively long half-life, that is approved by the European Commission for the treatment of advanced/metastatic RCC. Tivozanib, at very low serum concentration can inhibit phosphorylation of VEGFR -1, -2, and -3 tyrosine kinase activity. This article summarizes the clinical data on tivozanib in the treatment of advanced/metastatic RCC.en_US
dc.identifier.doi10.2147/CMAR.S206105
dc.identifier.endpage7785en_US
dc.identifier.issn1179-1322
dc.identifier.pmid31496820
dc.identifier.startpage7779en_US
dc.identifier.urihttps://doi.org/10.2147/CMAR.S206105
dc.identifier.urihttps://hdl.handle.net/11468/18782
dc.identifier.volume11en_US
dc.identifier.wosWOS:000481484700003
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherDove Medical Press Ltden_US
dc.relation.ispartofCancer Management and Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectVascular Endothelial Growth Factoren_US
dc.subjectTyrosine Kinase Inhibitorsen_US
dc.subjectTivozaniben_US
dc.subjectClear-Cell Carcinomaen_US
dc.titleImpact of tivozanib on patient outcomes in treatment of advanced renal cell carcinomaen_US
dc.titleImpact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu